U.S. markets closed

CSL Limited (CSLLY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
104.70+0.16 (+0.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close104.54
Open107.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range103.98 - 107.35
52 Week Range91.04 - 117.98
Volume46,638
Avg. Volume54,317
Market Cap94.919B
Beta (5Y Monthly)0.12
PE Ratio (TTM)35.82
EPS (TTM)2.92
Earnings DateN/A
Forward Dividend & Yield1.04 (0.99%)
Ex-Dividend DateMar 03, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching
    Simply Wall St.

    Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season
    PR Newswire

    New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

    Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines.1 This retrospective cohort analysis indicated QIVc was more effective in reducing hospitalizations/emergency room (ER) visits caused by influenza, respiratory related hospitalizations/ER visits and all-cause hospitalizations compared with an egg-based quadrivalent influenza vaccine (QIVe) among individuals 4–64 years of age during the 2018/19 U.S. influenza season.1

  • Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans
    CNW Group

    Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans

    Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /CNW/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).